# A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

> **NCT04995653** · PHASE1 · COMPLETED · sponsor: **Seres Therapeutics, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Vancomycin Pre-Treatment
- **DRUG:** Vancomycin Placebo
- **DRUG:** SER-155
- **DRUG:** SER-155 Placebo

## Key facts

- **NCT ID:** NCT04995653
- **Lead sponsor:** Seres Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-24
- **Primary completion:** 2024-07-23
- **Final completion:** 2024-07-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04995653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04995653, "A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04995653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*